ENTX · Entera Bio Ltd.
$3.23
-0.70 (-17.73%)
At close · Jul 28
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's current capital resources do not include the capital required to fully fund the Company's proposed Phase 3 program for EB613 in osteoporosis. These factors raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed May 8, 2026
Market Cap
$160.47M
Shares
49.23M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$42K
-76.8%
FY2025
Net Income
-$11.44M
-19.9%
FY2025
Gross Margin
0%
-5pp
FY2025
Operating Margin
-27450%
-22154.4pp
FY2025
Diluted EPS
$0.25
0%
FY2025
Operating Cash Flow
-$7.37M
-8.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $0 | $42K | $181K | $0 | $134K | $571K | $365K | |
| $0 | $42K | $172K | $0 | $101K | $373K | $300K | |
| $0 | $0 | $9000 | $0 | $33K | $198K | $65K | |
| — | 0% | 4.97% | — | 24.63% | 34.68% | 17.81% | |
| $7.13M | $6M | $4.5M | $4.51M | $5.85M | $6.77M | $6.38M | |
| $5.37M | $5.53M | $5.1M | $4.43M | $7.25M | $5.69M | $4.85M | |
| $403K | $398K | $340K | — | — | — | — | |
| $12.51M | $11.53M | $9.59M | $8.89M | $13.05M | $12.42M | $11.23M | |
| -$12.51M | -$11.53M | -$9.59M | -$8.89M | -$13.02M | -$12.22M | -$11.17M | |
| — | -27450% | -5295.58% | — | -9714.18% | -2139.58% | -3059.73% | |
| $128K | $90K | $58K | $31K | $83K | -$29K | -$28K | |
| — | -$11.44M | -$9.53M | -$8.86M | -$12.93M | -$12.25M | -$11.2M | |
| — | $0 | $14K | $29K | $137K | -$59K | $20K | |
| -$12.38M | -$11.44M | -$9.54M | -$8.89M | -$13.07M | -$12.19M | -$11.22M | |
| — | -27235.71% | -5271.27% | — | -9754.48% | -2134.33% | -3072.88% | |
| USD/shares | — | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 | — |
| USD/shares | — | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 | — |
| shares | — | 46.19M | 37.65M | 29.01M | 28.81M | 26.13M | 18.42M |
| shares | — | 46.19M | 37.65M | 29.01M | 28.81M | 26.13M | 18.42M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.85×
EV/EBIT
—
Peer median 26.92×
P/E (TTM)
12.54×
Peer median 4.37×
Peer medians compare against the 300 similar-size Biotechnology companies (of 522 listed).